Bristol-myers Squibb Pharma Company

Visen Medical, Inc.

Dupont Pharmaceuticals Company

Other

The Dupont Merck Pharmaceutical Company

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Bristol-myers Squibb Pharma Corporation

Milind Rajopadhye

Thomas David Harris

Edward H Cheesman

Alan P Carpenter, Jr

John A Barrett

Michael Sworin

Shuang Liu

Kevin Groves

Narasimhachari Narayanan

Jeffrey D Peterson

David Scott Edwards

Dorin V Preda

Prahlad R Singh

D Scott Edwards

Shaker Ahmed Mousa

Paul J Coleman

Farouc Amin Jaffer

William Frank Degrado

Guojie Ho

Bohumil Bednar

Le T Duong

Stuart J Heminway

John Andrew Barrett

Scott David Edwards

Jingwu Duan

Carl P Decicco

David J Nelson

Stuart D Heminway

Singh R Prahlad

Alan P Carpenter Jr

David Charles Onthank

Paul David Crane

This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N, N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof.

Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels

The invention provides methods and compositions for determining whether a subject containing a stent immobilized in a blood vessel has asymptomatic stent thrombosis or is at risk of developing clinically symptomatic stent thrombosis. In one approach, the method involves imaging a region of the blood vessel that contains the stent using a probe that contains a fluorochrome, for example, a near-infrared fluorochrome, and a targeting moiety that binds a molecular marker indicative of the presence of asymptomatic stent thrombosis or the development of symptomatic stent thrombosis. To the extent that the subject displays one or more such markers, the probe binds to the markers and increases the local concentration of the probe in the vicinity of the stent. The imaging method identifies those patients that display a higher density of such markers in the vicinity of the stent. As a result, those patients can be monitored for, and/or treated to prevent, symptomatic stent thrombosis.

Methods and compositions for identifying subjects at risk of developing stent thrombosis

Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.

Fluorescent imaging agents

The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent.

Biocompatible fluorescent metal oxide nanoparticles

The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.

Integrin targeting agents and in-vivo and in-vitro imaging methods using the same

This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N,N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof.

This invention relates to new fluorescent chemical entities, including fluorescent molecules that comprise a carboxyl or carbonyl functionalized pyridine moiety. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars, and their uses thereof.

Nicotinic acid and picolinic acid derived near-infrared fluorophores

Nicotinic and picolinic acid derived near-infrared fluorophores

This invention relates to new carbocyanine fluorophores comprising a biomolecule targeting moiety containing 1-6 aromatic moieties, wherein the targeting moiety is designed to attach to biocompatible molecules to form in vivo optical imaging agents.

Biocompatible fluorescent imaging agents

The present invention describes novel compounds of the formula:(Q)&#x2014;L&#x2014;C,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Vitronectin receptor antagonist pharmaceuticals

Growing community of inventors

Westford, MA, United States of America

Milind Rajopadhye